MedTrace Logo

The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

NCT00238082 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-03-29

No results posted yet for this study

Summary

This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

Conditions

Interventions

DRUG

HFA-134A Beclomethasone DIpropionate (QVAR)

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Richard Martin, MD · National Jewish Medical and Research Center faculty

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238082 on ClinicalTrials.gov